News · 26 weeks46+250%
2026-03-012026-08-23
Mix2990d
- Insider16(55%)
- SEC Filings6(21%)
- Other3(10%)
- Leadership2(7%)
- Earnings2(7%)
Latest news
25 items- INSIDERChief Executive Officer Getz Heather C bought $8,311 worth of shares (12,500 units at $0.66), increasing direct ownership by 2% to 532,500 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Executive Officer Getz Heather C bought $10,467 worth of shares (15,000 units at $0.70), increasing direct ownership by 3% to 520,000 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)
- SECAmendment: TELA Bio Inc. filed SEC Form 8-K: Leadership Update8-K/A - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 10-Q filed by TELA Bio Inc.10-Q - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Reports Second Quarter 2026 Financial ResultsMALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Announced appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026;Delivered international revenue growth of 26% over the prior year period, with continued momentum in several European markets;Achieved additional market share gain with OviTex unit volume growth of 12% over the prior year period;Grew LiquiFix revenue by 39% over the prior-year period; andDelivered $19.3
- INSIDERChief Executive Officer Getz Heather C was granted 500,000 shares, increasing direct ownership by 10,000% to 505,000 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERNew insider Getz Heather C claimed ownership of 5,000 shares (SEC Form 3)3 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company’s newly-hired Chief Executive Officer, Heather Getz, with a grant date of August 3, 2026 (the "Getz Grant Date"). The stock options consist of (i) stock options to purchase 1,365,000 shares of common stock (the "Standard Options") and (ii)
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Leadership Update8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and DirectorMALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the "Board") has appointed Heather Getz as Chief Executive Officer and Director, effective today. "As TELA Bio enters its next phase of growth and commercial execution, the Board is pleased to welcome Heather as our next Chief Executive Officer," said Joseph Capper, Chairman of the Board of TELA Bio. "Heather brings a proven track record of driving operational excellence, leading organizations through complex business and financial transformat
- PRTELA Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceMALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference at 8:30 am ET on August 12th, 2026. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical o
- PRTELA Bio to Announce Second Quarter 2026 Financial ResultsMALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes befor
- INSIDERDirector Plovanic William J. was granted 20,930 shares, increasing direct ownership by 89% to 44,530 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERDirector Capper Joseph H was granted 6,227 shares, increasing direct ownership by 26% to 29,827 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERDirector Rocchio Betty Jo was granted 11,675 shares, increasing direct ownership by 98% to 23,600 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERDirector Capper Joseph H was granted 23,600 shares (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERSEC Form 3 filed by new insider Capper Joseph H3 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERDirector Plovanic William J. was granted 11,675 shares, increasing direct ownership by 98% to 23,600 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERSEC Form 3 filed by new insider Neels Guido J3 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERDirector Neels Guido J was granted 23,600 shares (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERSEC Form 3 filed by new insider Thomas Paul3 - TELA Bio, Inc. (0001561921) (Issuer)
TELA FAQ
7 questionsWhat does TELA Bio Inc. do?
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be...Where does TELA stock trade?
TELA Bio Inc. (TELA) is listed on NASDAQ.What sector and industry is TELA in?
TELA Bio Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did TELA Bio Inc. go public?
TELA Bio Inc. (TELA) completed its IPO in 2019.What are analysts saying about TELA?
TELA Bio Inc. has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $200.00 price target on 2025-03-21.What companies are similar to TELA?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare TELA side-by-side with any of them on Quantisnow.How can I track TELA on Quantisnow?
Quantisnow aggregates TELA Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TELA to receive live email and push alerts on every new disclosure.